Clinical Trial Spotlight: Should a Third Generation EGFR Inhibitor be First Line Therapy for EGFR Mutation-Positive NSCLC?

GRACE Videos and Articles

Dr. Jack West introduces the question of whether third generation EGFR tyrosine kinase inhibitors osimertinib and rociletinib should be used as first line therapy rather than for acquired resistance, including discussing key clinical trials on the topic.

Get more information about the FLAURA Trial and TIGER-1 Trial.

 

 

Join the Conversation

Please feel free to offer comments and raise questions in our
discussion forums.

 Join The conversation